For patients with newly diagnosed, standard-risk B-cell acute lymphoblastic leukemia (ALL) with an average or high risk for ...

Brexucabtagene autoleucel showed comparable efficacy outcomes in patients aged 60 to 69 with relapsed/refractory B-cell acute ...

Children with newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL) lived significantly longer without disease ...

Medical Watch Digest for Dec. 9 Acute lymphoblastic leukemia highest survival rate among pediatric cancers Survival rates for childhood leukemia are improving thanks to new treatments. Acute ...

The feud between Arcellx and Legend Biotech over their anti-BCMA CAR-T therapies for multiple myeloma is getting extra spicy ...

For patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL), obecabtagene autoleucel (obe-cel), an ...

In a recent study published in Nature Cancer, researchers explore treatment resistance and relapse in T-cell acute ...

Ten years after its first FDA approval, Amgen’s Blincyto continues to make inroads in treating acute lymphoblastic leukemia. | Investigators halted study randomization early based on the strong ...

Adverse events associated with ponatinib in CML and ALL were shown to have decreased significantly since its approval, ...

B-cell acute lymphoblastic leukemia (B-cell ALL) is the most common childhood cancer. Despite a high overall cure rate, relapsed B-cell ALL remains a leading cause of cancer-related death among ...

Treatment with bicistronic CD19/CD22 CAR-T cell therapy has shown event-free survival improvements in children with relapsed ...